Table 1:
The clinical and pathological characterization of our patient population
| Flow Cytometry/Gene Expression/TCR sequencing | Cytof | Activation IFN-γ Studies | All Studies | |
|---|---|---|---|---|
| Total Number | 20 | 28 | 4 | 52 |
| Mean age at diagnosis | 51.3 years | 51.4 years | 43.1 years | 50.7 years |
| Diagnosis | Number (percent) | Number (percent) | Number (percent) | Number (percent) |
| Glioblastoma | 18 (90.0%) | 20 (71.4%) | 3 (75.0%) | 41 (78.8%) |
| Gliosarcoma | 0 (0%) | 1 (3.6%) | 0 (0%) | 1 (1.9%) |
| Anaplastic Oligodendroglioma | 0 (0%) | 3 (10.7%) | 0 (0%) | 3 (5.8%) |
| Anaplastic Astrocytoma | 2 (10.0%) | 4 (14.3%) | 1 (25.0%) | 7 (13.5%) |
| Sex | ||||
| Male | 13(65.0%) | 17 (60.7%) | 4 (100%) | 34 (65.4%) |
| Female | 7 (35.0%) | 11 (39.3%) | 9(0%) | 27 (51.9%) |
| IDH | ||||
| Mutated | 4 (20.0%) | 7 (25.0%) | 2 (50.0%) | 13 (25.0%) |
| Wildtype | 15 (75.0%) | 21 (75.0%) | 2 (50.0%) | 38 (73.1%) |
| Unknown | 1(5.0%) | 1 (1.9%) | ||
| MGMT | ||||
| Methylated | 10 (50.0%) | 11 (39.3%) | 0 (0%) | 21 (40.4%) |
| Non-methylated | 10 (50.0%) | 16 (57.1%) | 3 (75.0%) | 29 (55.8%) |
| Unknown | 1 (3.6%) | 1 (25.0%) | 2 (3.8%) | |
| Presentation | ||||
| New diagnosis | 14 (70.0%) | 16 (57.1%) | 0 (0%) | 30 (57.7%) |
| Recurrent | 6(40.0%) | 12 (42.9%) | 4(100%) | 22 (42.3%) |